Theranova Versus High-flux Dialyzer on Preservation of Residual Renal Function
Theranova Versus High-flux Dialyzer on Preservation of Residual Renal Function
Theranova is a novel medium cut-off dialyzer and has better performance for removal of middle
 molecules compared to conventional hemodialysis. The study investigates the effect of
 Theranova dialzyer on preserving residual renal function in the incident hemodialysis
 pateitns compared to high-flux dialzyer. The primary endpoint is change of glomerular
 filtration rate, calculated using creatinine and urea clearance. The secondary endpoints are
 glomerular filtration rate, daily urine volume, serum middle molecule concentrations,
 hospitalization, mortality, and patient reporeted outcomes.
Inclusion Criteria:

 -  Incident end-stage renal disease ESRD patient receiving hemodialysis for less than 1
 month

 -  18 years old and older

 -  Vascular access by arteriovenous fistula/graft

 -  Creatinine clearance of more than 2 ml/min

 -  Agreement to participate in the clinical study

 Exclusion Criteria:

 -  Dialysis through permanent catheter

 -  Plan for kidney transplantation within 6 months

 -  Severe volume overloading state

 -  Any hematologic malignancy or monoclonal gammopathy

 -  Any malignancy

 -  Active infectious disease

 -  HIV infection

 -  Patient enrolled to another study within 3 month from starting the present study